文献速递胸部肿瘤放疗放疗物理与技术

高风险非小细胞肺癌接受主动扫描质子束放疗与免疫治疗

High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy.
PubMed 文献 · Adv Radiat Oncol · 2022-11-24

本研究纳入29例因严重心肺功能障碍、既往胸部放疗史和/或病变体积大或位置不佳而被判定不适合常规X线放疗的高风险非小细胞肺癌患者,给予铅笔束扫描质子束治疗(PBS-PBT),多数患者接受6000 cGy(相对生物效应)分30次同步化疗。急性3级毒性共6例,无4级及以上毒性;2年无进展生存率和总生存率分别为51%和67%。

要点

  • 高风险非小细胞肺癌患者接受PBS-PBT,多数为6000 cGy分30次同步化疗。
  • 急性3级毒性共6例:食管炎4例(14%)、呼吸困难1例(3.5%)、咳嗽1例(3.5%),无4级及以上毒性。
  • 2年无进展生存率和总生存率分别为51%和67%,多数患者后续接受免疫治疗,高级别肺炎罕见。

核心结论

  • 在经仔细多学科评估和严密随访的前提下,对高风险肺癌患者行根治性PBS-PBT并联合免疫治疗是可行的。

研究设计与样本

  • 研究纳入29例高风险非小细胞肺癌患者,高风险定义为严重基础心肺功能障碍、既往胸部放疗史和/或病变体积大或位置不佳(如双侧肺门受累、锁骨上受累)。
  • 患者被判定不适合常规X线放疗,接受铅笔束扫描质子束治疗(PBS-PBT);4维CT模拟扫描显示任一维度呼吸运动大于1 cm者被判定不适合PBT。
  • 毒性采用不良事件通用术语标准(CTCAE)5.0版报告,总生存率和无进展生存率采用Kaplan-Meier法计算。

主要发现

  • 55%的患者因严重心肺功能障碍被定义为高风险。
  • 多数患者接受根治性总剂量6000 cGy(相对生物效应)分30次同步化疗。
  • 急性3级毒性共6例:食管炎4例(14%)、呼吸困难1例(3.5%)、咳嗽1例(3.5%);无患者发生4级或更高毒性。
  • 多数患者后续接受免疫治疗,高级别肺炎罕见。
  • 2年无进展生存率和总生存率估计分别为51%和67%;随访期间2例患者死亡被确认或怀疑由COVID-19导致。

临床怎么用

  • 作者认为,在仔细多学科评估和严密随访下,对高风险肺癌患者行根治性PBS-PBT联合免疫治疗是可行的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Non-small cell lung cancer (NSCLC) is a deadly malignancy that is frequently diagnosed in patients with significant medical comorbidities. When delivering local and regional therapy, an exceedingly narrow therapeutic window is encountered, which often precludes patients from receiving aggressive curative therapy. Radiation therapy advances including particle therapy have been employed in an effort to expand this therapeutic window. Here we report outcomes with the use of proton therapy with curative intent and immunotherapy to treat patients diagnosed with high-risk NSCLC. METHODS AND MATERIALS: Patients were determined to be high risk if they had severe underlying cardiopulmonary dysfunction, history of prior thoracic radiation therapy, and/or large volume or unfavorable location of disease (eg, bilateral hilar involvement, supraclavicular involvement). As such, patients were determined to be ineligible for conventional x-ray-based radiation therapy and were treated with pencil beam scanning proton beam therapy (PBS-PBT). Patients who demonstrated excess respiratory motion (ie, greater than 1 cm in any dimension noted on the 4-dimensional computed tomography simulation scan) were deemed to be ineligible for PBT. Toxicity was reported using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Overall survival and progression-free survival were calculated using the Kaplan-Meier method. RESULTS: A total of 29 patients with high-risk NSCLC diagnoses were treated with PBS-PBT. The majority (55%) of patients were defined as high risk due to severe cardiopulmonary dysfunction. Most commonly, patients were treated definitively to a total dose of 6000 cGy (relative biological effectiveness) in 30 fractions with concurrent chemotherapy. Overall, there were a total of 6 acute grade 3 toxicities observed in our cohort. Acute high-grade toxicities included esophagitis (n = 4, 14%), dyspnea (n = 1, 3.5%), and cough (n = 1, 3.5%). No patients developed grade 4 or higher toxicity. The majority of patients went on to receive immunotherapy, and high-grade pneumonitis was rare. Two-year progression-free and overall survival was estimated to be 51% and 67%, respectively. COVID-19 was confirmed or suspected to be responsible for 2 patient deaths during the follow-up period. CONCLUSIONS: Radical PBS-PBT treatment delivered in a cohort of patients with high-risk lung cancer with immunotherapy is feasible with careful multidisciplinary evaluation and rigorous follow-up.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Carrasquilla M, Paudel N, Collins BT, et al. High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy. Adv Radiat Oncol. 2022. PMID: 36578277. doi:10.1016/j.adro.2022.101125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。